Drug intelligence / Profile preview

JRF104

Development stage: Preclinical
Lead developer: Chengdu Jinruijiye Biotechnology
Modality: Small Molecules

Overview

JRF104 is a small molecule cyclin-dependent kinase (CDK) inhibitor being developed by Shenzhen Jinruijiye Biotechnology. It is currently in preclinical development for the treatment of solid tumors and brain tumors. As a CDK inhibitor, it is designed to disrupt the cell cycle in cancer cells, potentially offering a therapeutic approach for various malignancies, including those affecting the central nervous system. The drug is part of a pipeline focused on small molecule therapies for oncology and neurological conditions.

Targets

CDK (CDK family)

Beyond the preview

Go deeper on JRF104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRF104.

Explore the full profile